Current clinical and preclinical photosensitizers for use in photodynamic therapy

Journal of Medicinal Chemistry

Volumn 47, Issue 16, 2004, Pages 3897-3915

  Detty, Michael R ^a   Gibson, Scott L ^b   Wagner, Stephen J ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c HOLLAND LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID BENZYL ESTER; AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID METHYL ESTER; BENZOPORPHYRIN DERIVATIVE; BENZVIX; CHALCOGEN; EOSIN; HEMATOPORPHYRIN DERIVATIVE; MEROCYANINE; METHYLENE BLUE; PHOTOSENSITIZING AGENT; PHTHALOCYANINE DERIVATIVE; UNCLASSIFIED DRUG;

CHEMICAL STRUCTURE; CLINICAL FEATURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LASER COAGULATION; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PSORIASIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW;

ANIMALS; CATIONS; COLORING AGENTS; DRUG EVALUATION, PRECLINICAL; ERYTHROCYTES; HUMANS; MACULAR DEGENERATION; NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS;

EID: 3242772115     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040074b     Document Type: Review

References (165)

1. Jesionek, A.; von Tappeiner, H. On the treatment of skin cancers with fluorescent substances. Arch. Klin. Med. 1905, 82, 223-227.
2. Schwartz, S. K.; Abolon, K.; Vermund, H. Some relationships of porphyrins, x-rays and tumors. Univ. Minn. Med. Bull. 1955, 27, 7-8.
3. Lipson, R. L.; Baldes, E. J.; Olsen, A. M. The use of a derivative of hematoporphyrin in tumor detection. J. Natl. Cancer Inst. 1961, 26, 1-11.
4. Lipson, R. L.; Baldes, E. J. The photodynamic properties of a particular hematoporphyrin derivative. Arch. Dermatol. 1960, 82, 508-516.
5. Kato, H. Photodynamic therapy for lung cancer-a review of 19 years' experience. J. Photochem. Photobiol., B. 1998, 42, 96-99.
6. (a) Puolakkainen, P.; Schroder, T. Photodynamic therapy of gastrointestinal tumors: a review. Dig. Dis. 1992, 10, 53-60.
7. (b) Moesta, K. T.; Schlag, P.; Douglas, H. O., Jr.; Mang, T. S. Evaluating the role of photodynamic therapy in the management of pancreatic cancer. Lasers Surg. Med. 1995, 16, 84-92.
8. Bellnier, D. A.; Greco, W. R.; Loewen, G. M.; Nava, H.; Oseroff, A. R.; Pandey, R. K.; Tsuchida, T.; Dougherty, T. J. Population pharmacokinetics of the photodynamic therapy agent 2-(1-hexyloxyehyl)-2-devinyl pyropheophorbide-a in cancer patients. Cancer Res. 2003, 63, 1806-1813.
9. Prosst, R. L.; Wolfsen, H. C.; Gahlen, J. Photodynamic therapy for esophageal diseases: a clinical update. Endoscopy 2003, 35, 1059-1068.
10. Dilkes, M. G.; Benjamin, E.; Ovaisi, S.; Banerjee, A. S. Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases. J. Laryngol. Otol. 2003, 117, 713-717.
11. Jichlinski, P.; Leisinger, H.-J. Photodynamic therapy in superficial bladder cancer: Past, present and future. Urol. Res. 2001, 29, 396-405.
12. Nathan, T. R.; Whitelaw, D. E.; Chang, S. C.; Lees, W. R.; Ripley, P. M.; Payne, H.; Jones, L.; Parkinson, M. C.; Emberton, M.; Gilliam, A. R.; Mundy, A. R.; Bown, S. G. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J. Urol. 2002, 168, 1427-1432.
13. Baas, P.; Saarnak, A.; Oppelaar, H.; Neering, H.; Stewart, F. A. Photodynamic therapy with meta-tetrahydroxyphenylchlorin for basal cell carcinoma: a phase I/II study. Br. J. Dermatol. 2001, 145, 75-78.
14. Schweitzer, V. G. Photofrin-mediated photodynamic therapy for treatment of aggressive head and neck nonmelanomatous skin tumors in elderly patients. Laryngoscope 2001, 111, 1091-1098.
15. Zeitouni, N.; Oseroff, A. R.; Shieh, S. Photodynamic Therapy for nonmelanoma skin cancers. Current review and update. Mol. Immunol. 2003, 39, 1133-1136.
16. Pariser, D. M.; Lowe, N. J.; Stewart, D. M.; Jarratt, M. T.; Luck, A. W.; Pariser, R. J.; Yamauchi, P. S. Photodynamic therapy with topical methylaminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J. Am. Acad. Dermatol. 2003, 48, 227-232.
17. Freeman, M.; Vinciullo, C.; Francis, D.; Spelman, L.; Nguyen, R.; Fergin, P.; Thai, K.-E.; Murrell, D.; Weightman, W.; Anderson, C.; Reid, C.; Watson, A.; Foley, P. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J. Dermatol. Treat. 2003, 14, 99-106.
18. Wong, T.-W.; Aizawa, K.; Sheyhedin, I.; Wushur, C.; Kato, H. Pilot study of topical delivery of mono-L-aspartyl chlorin e6 (NPe6): Implication of topical NPe6-photodynamic therapy. J. Pharmacol. Sci. 2003, 93, 136-142.
19. (a) Morton, C. A. Methyl aminolevulinate (Metvix) photodynamic therapy-practical pearls. J. Dermatol. Treat. 2003, 14 (Suppl. 3), 23-26.
20. (b) Foley, P. Clinical Efficacy of methyl aminolevulinate (Metvix) photodynamic therapy. J. Dermatol. Treat. 2003, 14 (Suppl. 3), 15-22.
21. (c) Rhodes, L. E.; de Rie, M.; Enstrom, Y.; Groves, R.; Morken, T.; Goulden, V.; Wong, G. A,; Grob, J. J.; Varma, S.; Wolf, P, Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch. Dermatol. 2004, 140, 17-23.
22. Tsujino, I.; Anderson, G. S.; Sieber, F. Postirradiation hyperthermia selectively potentiates the merocyanine 540-sensitized photoinactivation of small cell lung cancer cells. Photochem. Photobiol. 2001, 73, 191-198.
23. Sato, Y.; Yamazaki, T.; Yasukawa, K.; Kaneita, Y.; Mochimaru, J.; Hanai, M.; Irie, T.; Kura, Y.; Sawada, U.; Horie, T. Merocyanine 540-mediated photodynamic therapy inhibits P-glycoprotein (P-gp) activity in adriamycin-resistant K562 cells. Gan to Kagaku Ryoho 1999, 26, 2195-2200.
24. Yamazaki, T.; Sieber, F. Effect of hypothermia on the merocyanine 540-mediated purging of hematopoietic cells. J. Hematother. 1997, 6, 31-39.
25. Anderson, G. S.; Tsujino, I.; Miyagi, K.; Sampson, R.; Sieber, F. Preferential inactivation of paediatric solid tumour cells by sequential exposure to Merocyanine 540-mediated photodynamic therapy and Edelfosine: implications for the ex vivo purging of autologous haematopoietic stem cell grafts. J. Photochem. Photobiol., B. 2003, 69, 87-95.
26. Miyagi, K.; Sampson, R. W.; Sieber-Blum, M.; Sieber, F. Crystal violet combined with Merocyanine 540 for the ex vivo purging of hematopoietic stem cell grafts. J. Photochem. Photobiol., B 2003, 70, 133-144.
27. Anderson, G. S.; Miyagi, K.; Sampson, R. W.; Sieber, F. Antitumor effect of Merocyanine 540-mediated photochemotherapy combined with Edelfosine: potential implications for the ex vivo purging of hematpoietic stem cell grafts from breast cancer patients. J. Photochem. Photobiol., B 2002, 63, 101-108.
28. Brasseur, N.; Menard, I.; Forget, A.; El Jastimi, R.; Hamel, R.; Molfino, N. A.; van Lier, J. E. Eradication of multiple myeloma and breast cancer cells by TH9402-mediated photodynamic therapy: implication for clinical ex vivo purging of autologous stem cell transplants. Photochem, Photobiol. 2000, 72, 780-787.
29. Daziano, J. P.; Humeau, L.; Henry, M.; Mannoni, P.; Chanon, M.; Chabannon, C.; Juillard, M. Preferential photoinactivation of leukemia cells by aluminum phthalocyanine. J. Photochem. Photobiol., B. 1998, 43, 128-135.
30. Szoimies, R. M.; Landthalor, M.; Karror, S. Non-oncologic indications for ALA-PDT. J. Dermatol. Treat. 2002, 13 (Suppl. 1), S13-S18.
31. Loman, J. A.; Morton, C. A. Photodynamic therapy: applications in dermatology. Expert Opin. Biol. Ther. 2002, 2, 45-53.
32. (a) Rechtman, E.; Ciulla, T. A.; Criswell, M. H.; Pollack, A.; Harris, A. An update on photodynamic therapy in age-related macular degeneration. Expert Opin. Pharmacother. 2002, 3, 931-938.
33. (b) Keam, S. J.; Scott, L. J.; Curran, M. P. Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation. Drugs 2003, 63, 2521-2554.
34. (c) Mueller, V. A.; Ruokonen, P.; Schellenbeck, M.; Hartmann, C.; Tetz, M. Treatment of Rubeosis iridis with photodynamic therapy with Verteporphin-a new therapeutic and prophylactic option for patients with the risk of neovascular glaucoma? Ophthalmic. Res. 2003, 35, 60-64.
35. Hayase, M.; Woodbaum, K. W.; Perlroth, J.; Miller, R. A.; Baumgardner, W.; Yock, P. G.; Yeung, A. Photoangioplasty with local motexafin lutetium delivery reduces macrophages in a rabbit post-balloon injury model. Cardiovasc. Res. 2001, 49, 449-455.
36. Chou, T. M.; Woodburn, K. W.; Cheong, W. F.; Lacy, S. A.; Sudhir, K.; Adelman, D. C.; Wahr, D. Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium. Catheter Cardiovasc. Interv. 2002, 57, 387-394.
37. Onu, P.; LaMuraglia, G. M.; Robert, W. G.; Hasan, T. Photodynamic therapy of arteries. A novel approach for treatment of intimal hyperplasia. Circulation 1992, 85, 1189-1196.
38. Kereiakes, D. J.; Szyniszewski, A. M.; Wahr, D.; Herrmann, H. C.; Simon, D. I.; Rogers, C.; Kramer, P.; Shear, W.; Yeung, A. C.; Shunk, K. A.; Chou, T. M.; Popm, J.; Fitzgerald, P.; Carroll, T. E.; Forer, D.; Adelman, D. C. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term result. Circulation 2003, 108, 1310-1315.
39. Wainwright, M. Local treatment of viral disease using photodynamic therapy. J. Antimicrob. Agents 2003, 21, 510-520.
40. Margolis-Nunno, H.; Ben-Hur, E.; Gottlieb, P.; Robinson, R.; Oetjen, J.; Horowitz, B. Inactivation by phthalocyanine photosensitization of multiple forms of human immunodeficiency virus in red cell concentrates. Transfusion 1996, 36, 743-750.
41. Rywkin, S.; Ben-Hur, E.; Malik, Z.; Prince, A. M.; Li, Y. S.; Kenney, M. E.; Oleinick, N. L.; Horowitz, B. New phthalocyanines for photodynamic virus inactivation in red blood cell concentrates. Photochem. Photobiol. 1994, 60, 165-170.
42. Wainwright, M.; Giddens, R. M. Phenothiazinium photosensitizers: choice in synthesis and application. Dyes Pigm. 2003, 57, 245-257.
43. Ben-Hur, E.; Chan, W. S,; Yim, Z.; Zuk, M. M.; Dayal, V.; Roth, N.; Heldman, E.; Lazo, A. Valeri, C. R.; Horowitz, B. Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine Pc 4 and red light. Dev. Biol. Stand. 2000, 102, 149-155; 1997, 65, 461-464.
44. Ben-Hur, E.; Chan, W. S,; Yim, Z.; Zuk, M. M.; Dayal, V.; Roth, N.; Heldman, E.; Lazo, A. Valeri, C. R.; Horowitz, B. Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine Pc 4 and red light. Dev. Biol. Stand. 2000, 102, 149-155; 1997, 65, 461-464.
45. Wainwright, M. The emerging chemistry of blood product disinfection. Chem. Soc. Rev. 2002, 31, 128-136.
46. Rywkin, S.; Ben-Hur, E.; Reid, M. E.; Oyen, R.; Ralph, H.; Horowitz, B. Selective protection against IgG binding to red cells treated with phthalocyanines and red light for virus inactivation. Tranfusion 1995, 35, 414-420.
47. Sharman, W. M.; Allen, C. M.; van Lier, J. E. Photodynamic therapeutics: basic principles and clinical applications. Drug Discovery Today 1999, 4, 507-517.
48. Wan, S.; Parrish, J. A.; Anderson, R. R.; Madden, M. Transmittance of nonionizing radiation in human tissue. Photochem. Photobiol. 1981, 34, 679-684.
49. Dougherty, T. J.; Marcus, S. L. Photodynamic therapy. Eur. J. Cancer 1992, 28A, 1734-1742.
50. (a) Dougherty, T. J.; Gomer, C. J.; Henderson, B. W.; Jori, G.; Kessel, D.; Korbelik, M.; Moan, J.; Peng, Q. Photodynamic therapy. J. Natl. Cancer Inst. 1998, 90, 889-905.
51. (b) Henderson, B. W.; Dougherty, T. J. How does photodynamic therapy work? Photochem. Photobiol. 1992, 55, 145-157.
52. Fingar, V. H.; Mang, T. S.; Henderson, B. W. Modification of photodynamic therapy-induced hypoxia by Fluosol DA (20%) and carbogen breathing in mice. Cancer Res. 1988, 48, 3350-3354.
53. Dennis, E. J.; Dolmans, G. C.; Fukumura, D.; Jain, R. K. TIMELINE: Photodynamic therapy for cancer. Nat. Rev. Cancer 2003, 3, 380-387.
54. Dougherty, T. J. Hematoporphyrin as a photosensitizer of tumors. Photochem. Photobiol. 1983, 38, 377-379.
55. Dougherty, T. J.; Potter, W. R.; Weishaupt, K. R. The structure of the active component of hematoporphyrin derivative. Prog. Clin. Biol. Res. 1984, 170, 301-314.
56. Bellnier, D. A.; Dougherty, T. J. A preliminary pharmacokinetic study of intravenous photofrin in patients. J. Clin. Laser Med. Surg. 1996, 14, 311-314.
57. Sternberg, E. D.; Dolphin, D.; Brückner, C. Porphyrin-based photosensitizers for use in photodynamic therapy. Tetrahedron 1998, 54, 4151-4202.
58. Wilkinson, F.; Helman, W. P.; Ross, A. B. Quantum yields for the photosensitized formation of the lowest electronically excited singlet state of molecular oxygen in solution. J. Phys. Chem. Ref. Data 1993, 22, 113-262.
59. (a) Kessel, D.; Thompson, P.; Saatio, K.; Nantwi, K. D. Tumor localization and photosensitization by sulfonated derivatives of tetraphenylporphine. Photochem. Photobiol, 1987, 45, 787-790.
60. (b) Berg, K.; Prydz, K.; Moan, J. Photochemical treatment with the lysosomally localized dye tetra(4-sulfonatophenyl)porphine results in lysosomal release of the dye but not of β-N-acetyl-D-glucosamidase activity. Biochim. Biophys. Acta 1993, 1158, 300-306.
61. (c) Kessel, D.; Woodburn, K. Biodistribution of photosensitizing agents. Int. J. Biochem. 1993, 25, 1377-1383.
62. Sema, A. A. F.; Kennedy, J. C.; Blakeslee, D.; Robertson, D. M. Experimental porphyric neuropathy: a preliminary report. Can. J. Neurol. Sci. 1981, 8, 105-114.
63. 4 and its relation to photodynamic therapy. Photochem. Photobiol. 1987, 46, 801-807.
64. Harth, E. M.; Hecht, S.; Helms, B.; Malmstrom, E. E.; Fréchet, J. M. J.; Hawker, C. J. The effect of macromolecular architecture in nanomaterials: a comparison of site isolation in porphyrin core dendrimers and their isomeric linear analogues. J. Am. Chem. Soc. 2002, 124, 3926-3938.
65. Nishiyama, N.; Stapert, H. R.; Zhang, G.-D.; Takasu, D.; Jiang, D.-L.; Nagano, T.; Aida, T.; Kataoka, K. Light-harvesting ionic dendrimer porphyrins as new photosensitizers for photodynamic therapy. Bioconjugate Chem. 2003, 14, 58-66.
66. Gradl, S. N.; Felix, J. P.; Isacoff, E. Y.; Garcia, M. L.; Trauner, D. Protein surface recognition by rational design: nanomolar ligands for potassium channels. J. Am. Chem. Soc. 2003, 125, 12668-12669.
67. Latos-Grazynski, L.; Lisowski, J.; Olmstead, M. M.; Balch, A. L. Five-coordinate complexes of 21-thiaporphyrin. The preparation, spectra, and structures of iron(II), nickel(II), and copper-(II) complexes. Inorg. Chem. 1989, 28, 1183-1188.
68. Latos-Grazynski, L.; Pacholska, E.; Chmielewski, P. J.; Olmstead, M. M.; Balch, A. L. Synthesis of 5,20-diphenyl-10,15-bis-(p-tolyl)-21-selenaporphyrin (SeDPDTPH). Inorg. Chem. 1996, 35, 566-573.
69. Ziolkowski, P.; Milach, J.; Symonowicz, K.; Chmielewski, P.; Latos-Grazynski, L.; Marcinkowska, E. 5,20-Bis(4-sulphophenyl)-10,15-bis(2- methoxy-4-sulfophenyl)-21-thiaporphyrin as a new potent sensitizer in photodynamic therapy. Tumori 1995, 81, 364-369.
70. Marcinkowska, E.; Ziolkowski, P.; Pacholska, E.; Latos-Grazynski, L.; Chmielewski, P.; Radzikowski, C. Z. The new sensitizing agents for photodynamic therapy: 21-selenaporphyrin and 21-thiaporphyrin. Anticancer Res. 1997, 17, 3313-3320.
71. Hilmey, D. G.; Abe, M.; Nelen, M. I.; Stilts, C. E.; Baker, G. A.; Baker, S. N.; Bright, F. V.; Davies, S. R.; Gollnick, S. O.; Oseroff, A. R.; Gibson, S. L.; Hilf, R.; Detty, M. R. Water-soluble, core-modified porphyrins as novel longer-wavelength-absorbing sensitizers for photodynamic therapy. 2. Effects of core heteroatoms and meso-substituents on biological activity. J. Med. Chem. 2002, 45, 449-461.
72. Pushpan, S. K.; Srinivasan, A.; Anand, V. R. G.; Chandrashekar, T. K.; Subramanian, A.; Roy, R.; Sugiura, K.; Sakata, Y. Inverted meso-aryl porphyrins with heteroatoms: characterization of thia, selena, and oxa N-confused porphyrins. J. Org. Chem. 2001, 66, 153-161.
73. Ulman, A.; Manassen, J. Synthesis of tetraphenylporphyrin molecules containing heteroatoms other than nitrogen. Part 4. Symmetrically and unsymmetrically substituted tetraphenyl-21,23-dithiaporphyrins. J. Chem. Soc., Perkin Trans. 1 1979, 4, 1066-1069.
74. Ulman, A.; Manassen, J.; Frolow, F.; Rabinovich, D. Synthesis of new tetraphenylporphyrin molecules containing heteroatoms other than nitrogen: II. Tetraphenyl-21-selena-23-thiaporphyrin and tetraphenyl-21,23-diselenaporphyrin. Tetrahedron Lett. 1978, 167-170.
75. Stilts, C. E.; Nelen, M. I.; Hilmey, D. G.; Davies, S. R.; Gollnick, S. O.; Oseroff, A. R.; Gibson, S. L.; Hilf, R.; Detty, M. R. Water-soluble, core-modified porphyrins as novel, longer-wavelength-absorbing sensitizers for photodynamic therapy. J. Med. Chem. 2000, 43, 2403-2410.
76. Meng, G. G.; James, B. R.; Skov, K. A.; Korbelik, M. Porphyrin chemistry pertaining to the design of anti-cancer drugs; part 2, the synthesis and in vitro tests of water-soluble porphyrins containing in the meso positions, the functional groups: 4-methylpyridinium, 4-sulfonatophenyl, in combination with phenyl, 4-pyridyl, 4-nitrophenyl, or 4-aminophenyl. Can. J. Chem. 1994, 71, 2447-2457.
77. You, Y.; Gibson, S. L.; Hilf, R.; Davies, S. R.; Oseroff, A. R.; Roy, I.; Ohulchanskyy, T. Y.; Bergey, E. J.; Detty, M. R. Water soluble, core-modified porphyrins. 3. Synthesis, photophysical properties, and in vitro studies of photosensitization, uptake, and localization with carboxylic acid-substituted derivatives. J. Med. Chem. 2003, 46, 3734-3747.
78. El-Sharabasy, M. M.; El-Waseef, A. M.; Hafez, M. M.; Salim, S. A. Porphyrin metabolism in some malignant diseases. Br. J. Cancer 1992, 65, 409-412.
79. Peng, Q.; Berg, K.; Moan, J.; Kongshaug, M.; Nesland, J. M. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem. Photobiol. 1997, 65, 235-251.
80. Exadaktylou, D.; Kurwa, H. A.; Calonje, E.; Barlow, R. J. Treatment of Darier's disease with photodynamic therapy. Br. J. Dermatol. 2003, 149, 606-610.
81. Gaullier, J. M.; Berg, K.; Peng, Q.; Anholt, H.; Selbo, P. K.; Ma, L. W.; Moan, J. Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res. 1997, 57, 1481-1486.
82. (a) Kennedy, J. C.; Pottier, R. H.; Pross, D. C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J. Photochem. Photobiol. B 1990, 6, 143-148.
83. (b) Kennedy, J. C.; Marcus, S. L.; Pottier, R. H. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J. Clin. Laser Mod. Surg. 1996, 14, 289-304.
84. Verma, A.; Nye, J. S.; Snyder, S. H. Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 2256-2260.
85. Chakraborti, A. S. Interaction of porphyrins with heme proteins-a brief review. Mol. Cell. Biochem. 2003, 253, 49-54.
86. Rahimipour, S.; Ben-Aroya, N.; Ziv, K.; Chen, A.; Fridkin, M.; Koch, Y. Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues. J. Med. Chem. 2003, 46, 3965-3974.
87. Paquette, B.; Boyle, R. W.; Ali, H.; MacLennan, A. H.; Truscott, T. G.; van Lier, J. E. Sulfonated phthalimidomethyl aluminum phthalocyanine: The effect of hydrophobic substituents on the in vitro phototoxicity of phthalocyanines.
88. Margarone, P.; Grégoire, M.-J.; Scasnárt, V.; Ali, H.; van Lier, J. E. Structure-photodynamic relationships of a series of 4-substituted zinc phthalocyanines. Photochem. Photobiol. 1996, 63, 217-223.
89. Berg, K.; Bommer, J. C.; Moan, J. Evaluation of sulfonated aluminum phtahocyanines for use in photochemotherapy. A study on the relative efficiencies of photoinactivation. Photochem. Photobiol. 1989, 49, 587-594.
90. Colussi, V. C.; Feyes, D. K.; Mulvihill, J. W.; Li, Y.-S.; Kenney, M. E.; Elmets, C. A.; Oleinick, N. L.; Mukhtar, H. Phthalocyanine 4 (Pc4) photodynamic therapy of human OVCAR-3 tumor xenografts. Photochem. Photobiol. 1999, 69, 236-241.
91. Boyle, R. W.; Paquette, B.; van Lier, J. E. Biological activities of phthalocyanines XIV. Effect of hydrophobic phthalimidomethyl groups on the in vivo phototoxicity and mechanism of photodynamic action of sulphonated aluminum phthalocyanines. Br. J. Cancer 1992, 65, 813-817.
92. 6 in the photodynamic therapy of malignant tumors. J. Photochem. Photobiol., B 1994, 22, 211-217.
93. Li, G.; Graham, A.; Chen, Y.; Dobhal, M. P.; Morgan, J.; Zheng, G.; Kozyrev, A.; Oseroff, A.; Dougherty, T. J.; Pandey, R. K. Synthesis, comparative photosensitizing efficacy, human serum albumin (site II) binding ability, and intracellular localization characteristics of novel benzobacteriochlorins derived from vicdihydroxybacteriochlorins. J. Med. Chem. 2003, 46, 5349-5359.
94. Borle, F.; Radu, A.; Monnier, P.; van den Bergh, H.; Wagnieres, G. Evaluation of the photosensitizer Tookad for photodynamic therapy on the Syrian golden hamster cheek pouch model: light dose, drug dose, and drug-light interval effects. Photochem. Photobiol. 2003, 78, 377-383.
95. Huang, Z.; Chen, Q.; Brun, P.-H.; Wilson, B. C.; Scherz, A.; Salomon, Y.; Luck, D. L.; Beckers, J.; Hetzel, F. W. Studies of a novel photosensitizer Pd-bacteriopheophorbide (Tookad) for the prostate cancer PDT in canine model. Proc. SPIE-Int. Soc. Opt. Eng. 2003, 5254 (Photonics and Imaging in Biology and Medicine), 83-90.
96. Wyss, P.; Schwarz, V.; Dobler-Girdziunaite, D.; Hornung, R.; Walt, H.; Degen, A.; Fehr, M. K. Photodynamic therapy of locoregional breast cancer recurrences using a chlorin-type photosensitizer. Int. J. Cancer 2001, 93, 720-724.
97. Friberg, E. G.; Cunderlikova, B.; Pettersen, E. O.; Moan, J. pH effects on the cellular uptake of four photosensitizing drugs evaluated for use in photodynamic therapy of cancer. Cancer Lett. 2003, 195, 73-80.
98. Teiten, M.-H.; Marchal, S.; D'Hallewin, M. A.; Guillemin, F.; Bezdetnaya, L. Primary photodamage sites and mitochondrial events after Foscan photosensitization of MCF-7 human breast cancer cells. Photochem. Photobiol. 2003, 78, 9-14.
99. Cramers, P.; Ruevekamp, M.; Oppelaar, H.; Dalesio, O.; Baas, P.; Stewart, F. A. Foscan uptake and tissue distribution in relation to photodynamic therapy. Br. J. Cancer 2003, 88, 283-290.
100. Teiten, M. H.; Bezdetnaya, L.; Merlin, J. L.; Bour-Dill, C.; Pauly, M. E.; Dicato, M.; Guillemin, F. Effect of meta-tetra(hydroxyphenyl)chlorin (mTHPC)-mediated photodynamic therapy on sensitive and multidrug-resistant human breast cancer cells. J. Photochem. Photobiol., B 2001, 62, 146-152.
101. Bourre, L.; Simonneaux, G.; Ferrand, Y.; Thibaut, S.; Lajat, Y.; Patrice, T. Synthesis, and in vitro and in vivo evaluation of a diphenylchlorin sensitizer for photodynamic therapy. J. Photochem. Photobiol., B 2003, 69, 179-192.
102. Ferrand, Y.; Bourre, L.; Simonneaux, G.; Thibaut, S.; Odobel, F.; Lajat, Y.; Patrice, T. Hydroporphyrins as tumor photosensitizers: synthesis and photophysical studies of 2,3-dihydro-5,-15-di(3,5-dihydroxyphenyl) porphyrin. Bioorg. Med. Chem. Lett. 2003, 13, 833-835.
103. Detty, M. R. Photosensitisers for the photodynamic therapy of cancer and other diseases. Expert Opin. Ther. Pat. 2001, 11, 1849-1860.
104. Krueger, T.; Altermatt, H. J.; Mettler, D.; Scholl, B.; Magnusson, L.; Ris, H. B. Experimental photodynamic therapy for malignant pleural mesothelioma with pegylated mTHPC. Lasers Surg. Med. 2003, 32, 61-68.
105. Reuther, T.; Kibler, A. C.; Zillman, U.; Flechtenmachey, C.; Sinn, H. Comparison of the in vivo efficiency of Photofrin II-, mTHPC-, mTHPC-PEG- and mTHPCnPEG-mediated PDT in a human xenografted head and neck carcinoma. Lasers Surg. Med. 2001, 29, 314-322.
106. Laville, I.; Figueiredo, T.; Loock, B.; Pigaglio, S.; Maillard, P.; Grierson, D. S.; Carrez, D.; Croisy, A.; Blais, J. Synthesis, cellular internalization and photodynamic activity of glucoconjugated derivatives of tri and tetra(meta-hydroxyphenyl)chlorins. Bioorg. Med. Chem. 2003, 11, 1643-1652.
107. Potter, W. R.; Henderson, B. W.; Bellnier, D. A.; Pandey, R. K.; Vaughan, L. A.; Weishaupt, K. R.; Dougherty, T. J. Parabolic quantitative structure-activity relationships and photodynamic therapy: application of a three-component model with clearance to the in vivo quantitative structure-activity relationships of a congeneric series of pyropheophorbide derivatives used as photosensitizers for photodynamic therapy. Photochem. Photobiol. 1999, 70, 781-788.
108. Sessler, J. L.; Hemmi, G.; Mody, T. D.; Murai, T.; Burrell, A.; Young, S. W. Texaphyrins: synthesis and applications. Acc. Chem. Res. 1994, 27, 43-50.
109. Sessler, J. L.; Miller, R. A.; Texaphyrins-new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem. Pharmacol. 2000, 59, 733-739.
110. Bernhard, E. J.; Mitchell, J. B.; Deen, D.; Cardell, M.; Rosenthall, D. I.; Brown, J. M. Re-evaluating gadolinum(III) texaphyrin as a radiosensitizing agent. Cancer Res. 2000, 60, 86-91.
111. Peng, Q.; Moan, J.; Ma, L. W.; Nesland, J. M. Uptake, localization, and photodynamic effect of meso-tetra(hydroxyphenyl)porphine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma. Cancer Res. 1995, 55, 2620-2626.
112. Oleinick, N. L.; Morris, R. L.; Belichenko, I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem. Photobiol. Sci. 2002, 1, 1-21.
113. Figge, F. H. G.; Weiland, G. S.; Manganiello, L. O. J. Cancer detection and therapy. Affinity of neoplastic, embryonic, and traumatized tissue for porphyrins and metalloporphyrins. Proc. Soc. Exp. Biol. Med. 1948, 68, 640-641.
114. Diamond, I.; McDonagh, A. F.; Wilson, C. B.; Granelli, S. G.; Nielsen, S.; Jaenicke, R. Photodynamic therapy of malignant tumors. Lancet 1972, 2, 1175-1177.
115. Hilf, R.; Murant, S.; Narayanan, U.; Gibson, S. L. Relationship of mitochondrial function and cellular adenosine triphosphate levels to hematoporphyrin derivative-induced photosensitization in R3230AC mammary tumors. Cancer Res. 1986, 46, 211-217.
116. Gibson, S. L.; Murant, R. S.; Chazen, M. D.; Kelly, M. E.; Hilf, R. In vitro photosensitization of tumor cell enzymes by Photofrin II administered in vivo. Br. J. Cancer 1989, 59, 47-53.
117. Verma, A.; Facchina, S. L.; Hirsch, D. J.; Song, S. Y.; Dillahey, L. F.; Williams, J. R.; Snyder, S. H. Photodynamic tumor therapy: Mitochondrial benzodiazepine receptors as a therapeutic target. Mol. Med. 1998, 4, 40-45.
118. Grabara, A.; Li, G.; Chen, Y.; Morgan, J.; Oseroff, A.; Dougherty, T. J.; Pandey, R. K. Structure-activity relationship of new octaethylporphyrin-based benzochlorins as photosensitizers for photodynamic therapy. Photochem. Photobiol. 2003, 77, 561-566.
119. Kessel, D.; Antolovich, M.; Smith, K. M. The role of the peripheral benzodiazepine receptor in the apoptotic response to photodynamic therapy. Photochem. Photobiol. 2001, 74, 346-349.
120. Morris, R. L.; Varnes, M. E.; Kenney, M. E.; Li, Y.-S.; Azizuddin, K.; McEnery, M. W.; Oleinick, N. L. The peripheral benzodiazepine receptor photodynamic therapy with the phthalocyanine photosensitizer Pc4. Photochem. Photobiol. 2002, 75, 652-661.
121. Goff, B. A.; Blumberg, M.; Hasan, T. Photoimmunotherapy of ovarian carcinoma cells ex vivo. Cancer Res. 1991, 51, 4762-4767.
122. (a) Yan, F.; Kopelman, R. The embedding of meta-tetra(hydroxyphenyl) chlorin into silica nanoparticle platforms for photodynamic therapy and their singlet oxygen production and pH-dependent optical properties. Photochem. Photobiol. 2003, 78, 587-591.
123. (b) Roy, I.; Ohulchanskyy, T. Y.; Pudavar, H. E.; Bergey, E. J.; Oseroff, A. R.; Morgan, J.; Dougherty, T. J.; Prasad, P. N. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J. Am. Chem. Soc. 2003, 125, 7860-7865.
124. Johnson, L. V.; Walsh, M. L.; Bockus, B. J.; Chen, L. B. Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy. J. Cell. Biol. 1981, 88, 526-535.
125. Davis, S.; Weiss, M. J.; Wong, J. R.; Lampidis, T. J.; Chen, L. B. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by breast adenocarcinoma-derived MCF-7 cells. J. Biol. Chem. 1985, 260, 13844-13850.
126. Bernal, S. D.; Lampdis, T. J.; McIsaac, R. M.; Chen, L. B. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science 1986, 222, 169-172.
127. Sun, X.; Wong, J. R.; Song, K.; Hu, J.; Garlid, K. D.; Chen, L. B. AA1, a newly synthesized monovalent lipophilic cation, expresses potent in vivo antitumor activity. Cancer Res. 1994, 54, 31465-1471.
128. Kessel, D.; Woodburn, K.; Henderson, B. W.; Chang, C. K. Sites of photodamage in vivo and in vitro by a cationic porphyrin. Photochem. Photobiol. 1995, 62, 875-881.
129. (a) Powers, S. K.; Walstad, D. L.; Brown, J. T.; Detty, M. R.; Watkins, P. J. Photosensitization of human glioma cells by chalcogenapyrylium dye. J. Neurol. Oncol. 1989, 7, 179-187.
130. (b) Detty, M. R.; Merkel, P. B.; Hilf, R.; Gibson, S. L.; Powers, S. K. Chalcogenapyrylium dyes as photochemotherapeutic agents. 2. Tumor uptake, mitochondrial targeting, and singlet-oxygen-induced inhibition of cytochrome c oxidase. J. Med. Chem. 1990, 33, 1108-1116.
131. Bellnier, D. A.; Young, D. N.; Detty, M. R.; Camacho, S.; Oseroff, A. R. pH-dependent chalcogenopyrylium dyes as potential sensitizers for PDT. Selective retention in tumor by exploiting pH differences between tumor and normal tissue. Photochem. Photobiol. 1999, 70, 630-636.
132. Kessel, D.; Woodburn, K. Selective photodynamic inactivation of a multidrug transporter by a cationic photosensitizing agent. Br. J. Cancer 1995, 71, 306-310.
133. 2+-dependent and caspace-3-independent apoptosis caused by damage in Golgi apparatus due to 2,4,5,7-tetrabromorhodamine 123 bromide-induced photodynamic effects. Photochem. Photobiol. 2003, 78, 241-247.
134. (a) Detty, M. R.; Prasad, P. N.; Donnelly, D. J.; Ohulchanskyy, T. Y.; Gibson, S. L.; Hilf, R. Synthesis, properties, and photodynamic properties in vitro of heavy-chalcogen analogues of tetramethylrosamine. Bioorg. Med. Chem. 2004, 12, 2537-2544.
135. (b) Ohulchanskyy, T. Y.; Donnelly, D. J.; Detty, M. R.; Prasad, P. N. Heteroatom substitution induced changes in excited-state photophysics and singlet oxygen generation in chalcogenoxanthylium dyes: effect of sulfur and selenium substitutions. J. Phys. Chem. B 108, 8668-8672.
136. (a) Brennan, N. K.; Hall, J. P.; Davies, S. R.; Gollnick, S. O.; Oseroff, A. R.; Gibson, S. L.; Hilf, R.; Detty, M. R. In vitro photodynamic properties of chalcogenopyrylium analogues of the thiopyrylium antitumor agent AA1. J. Med. Chem. 2002, 45, 5123-5135.
137. (b) Detty, M. R.; Gibson, S. L.; Hilf, R. Comparison of the dark and light-induced toxicity of thio and seleno analogues of the thiopyrylium dye AA1. Bioorg. Med. Chem. 2004, 12, 2589-2596.
138. Leonard, K. A. Hall, J. P.; Nelen, M. I.; Davies, S. R.; Gollnick, S. O.; Camacho, S.; Oserof, A. R.; Gibson, S. L.; Hilf, R.; Detty, M. R. A selenopyrylium photosensitizer for photodynamic therapy related in structure to the antitumor agent AA1 with potent in vivo activity and no long-term skin photosensitization. J. Med. Chem. 2000, 43, 4488-4498.
139. Wagner, S. J. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus. Med. Rev. 2002, 16, 61-66.
140. Noodt, B. B.; Rodal, G. H.; Wainwright, M.; Peng, Q.; Horobin, R.; Nesland, J. M.; Berg, K. Apoptosis induction by different pathways with methylene blue derivative and light from mitochondrial sites in V79 cells. Int. J. Cancer 1998, 75, 941-948.
141. Millish, K. J.; Cox, R. D.; Vernon, D.; Griffiths, J.; Brown, S. B. In vitro photodynamc activity of a series of methylene blue analogues. Photochem. Photobiol. 2002, 75, 392-397.
142. Lin, C. W.; Shulk, J. R.; Kirley, S. D.; Bachelder, C. M.; Flotte, T. J.; Sherwood, M. E.; Cincotta, L.; Foley, J. W. Photodynamic destruction of lysosomes mediated by nile blue photosensitizer. Photochem. Photobiol. 1993, 58, 81-91.
143. Cincotta, L.; Foley, J. W.; MacEachern, T.; Lampras, E.; Cincotta, A. H. Novel photodynamic effects of a benzophenothiazine on two different murine sarcomas. Cancer Res. 1994, 54, 1249-1258.
144. Morgan, J.; Whitaker, J. E.; Oseroff, A. R. GRP78 induction by calcium ionophore potentiates photodynamic therapy using the mitochondrial targetting dye victoria blue BO. Photochem. Photobiol. 1998, 67, 155-164.
145. Wainwright, M.; Phoenix, D. A.; Burrow, S. M.; Waring, J. Cytotoxicity and adjuvant activity of cationic photosensitizers in a multidrug-resistant cell line. J. Chemother. 1999, 11, 61-68.
146. Ara, G.; Aprille, J. R.; Malis, C. D.; Kane, S. B.; Cincotta, L.; Foley, J.; Bonventre, J. V.; Oseroff, A. R. Mechanisms of mitochondrial photosensitization by the cationic dye, N,N′-bis-(2-ethyl-1,3-dioxylene) kryptocyanine (EDKC): preferential inactivation of complex I in the electron transport chain. Cancer Res. 1987, 47, 6580-6585.
147. Modica-Napolitano, J. S.; Weiss, M. J.; Chen, L. B.; Aprille, J. R. Rhodamine 123 inhibits energetic function in isolated rat liver mitochondria. Biochem. Biophys. Res. Commun. 1984, 118, 717-723.
148. Modica-Napolitano, J. S.; Brunelli, B. T.; Koya, K.; Chen, L. B. Photoactivation enhances the mitochondrial toxicity of the cationic rhodacyanine MKT-077. Cancer Res. 1998, 58, 71-75.
149. Delaey, E. M.; Vantieghem, A. M.; Derycke, A.; Agostinis, P. M.; de Witte, P. A. In vitro photobiological evaluation of Rhodac, a new rhodacyanine photosensitizer. Photochem. Photobiol. 2001, 74, 331-338.
150. Chanh, T. C.; Allan, J. S.; Pervaiz, S.; Matthews, J. L.; Trevino, S. R.; Gulliya, K. S. Preactivated merocyanine 540 inactivates HIV-1 and SIV: potential therapeutic and blood banking applications. J. Acquired Immune Defic. Syndr. 1992, 5, 188-195.
151. Matthews, J. L.; Sogandares-Bernal, F.; Judy, M. M.; Marengo-Rowe, A. J.; Leveson, J. E.; Skiles, H.; Newman, J. T.; Chanh, T. C. Preliminary studies of photoinactivation of human immunodeficiency virus in blood. Transfusion 1991, 31, 636-641.
152. Neyndorff, H. C.; Bartel, D. L.; Tufaro, F.; Levy, J. G. Development of a model to demonstrate photosensitizer-mediated viral inactivation in blood. Transfusion 1990, 30, 485-490.
153. Sieber, F.; Krueger, G. J.; O'Brien, J. M.; Schober, S. L.; Burns, W. H.; Sharkis, S. J.; Sensenbrenner, L. L. Inactivation of Friend erythroleukemia virus and Friend virus-transformed cells by merocyanine 540-mediated photosensitization. Blood 1989, 73, 345-350.
154. O'Brien, J. M.; Gaffney, D. K.; Sieber, F. Sterilization of blood products by merocyanine 540-sensitized photoirradiation: Integrity of red cells and mechanism of action. Blood 1989, 74, 295a (abstract 1119).
155. Olson, J. M.; Ciliax, B. J.; Mancini, W. R.; Young, A. B. Presence of peripheral-type benzodiazepine binding sites on human erythrocyte membranes. Eur. J. Pharmacol. 1988, 152, 47-53.
156. (a) OhUigin, C.; McConnell, D. J.; Kelley, J. M.; van der Putten, W. J. Methylene blue photosensitized strand cleavage of DNA: effects of dye binding and oxygen. Nucleic Acids Res. 1987, 15, 7411-7427.
157. (b) Mohammad, T.; Morrison, H. Photonuclease activity of Taylor's blue. Bioorg. Med. Chem. Lett. 1999, 9, 2249-2254.
158. (c) Wagner, S. J.; Skripchenko, A.; Robinette, D.; Foley, J. W.; Cincotta, L. Factors affecting virus photoinactivation by a series of phenothiazine dyes. Photochem. Photobiol. 1998, 67, 343-349.
159. Paardekooper, M.; Van den Broek, P. J.; De Bruijne, A. W.; Elferink, J. G.; Dubbelman, T. M.; Van Steveninck, J. Photodynamic treatment of yeast cells with the dye toluidine blue: all-or-none loss of plasma membrane properties. Biochim. Biophys. Acta 1992, 1108, 86-90.
160. Skripchenko, A.; Robinette, D.; Wagner, S. J. Comparison of methylene blue and methylene violet for photoinactivation of intracellular and extracellular virus in red cell suspensions. Photochem. Photobiol. 1997, 65, 451-455.
161. Wagner, S.; Skripchenko, A.; Thompson-Montgomery, D. Use of a flow-cell system to investigate virucidal dimethylmethylene blue phototreatment in two RBC additive solutions. Transfusion 2002, 42, 1200-1205.
162. Pooler, J. P. The kinetics of colloid osmotic hemolysis. II. Photohemolysis. Bichim. Biophys. Acta 1985, 812, 199-205.
163. Wagner, S. J.; Skripchenko, A.; Thompson-Montgomery, D. Quinacrine enhances vesicular stomatitis virus inactivation and diminishes hemolysis of dimethylmethylene blue-phototreated red cells. Photochem. Photobiol. 2002, 76, 514-517.
164. Yamamoto, N.; Okamoto, T.; Kawaguchi, M. Novel intercalators of pyrylium dye into double-stranded DNA. Nucleic Acids Symp. Ser. 1993, 29, 83-84.
165. Skripchenko, A.; Wagner, S. J. Thiopyrylium as a new photosensitizer for pathogen inactivation: enhanced red cell preservation after thiopyrylium phototreatment using dye binding competitive inhibitor. Blood 2003, 102, 3022.